Fluoxetine-psychedelic drug-drug interaction research generates at least five independent replication studies published in peer-reviewed journals by 2028-04-29

Fluoxetine is Prozac, one of the most common antidepressants. Early research suggests it might interact badly with psychedelics, making them less effective or more dangerous. Scientists want to confirm this is real, but they need five separate research teams to run the same experiment and get the same results. That's hard to do in two years — it takes time to recruit people, run the study, and publish the results.

The original prediction bundled three distinct claims (five replications, two federal funding awards, new screening criterion) into one, making it difficult to falsify cleanly. Split into measurable components. The replication claim is the most tractable: SSRI-psychedelic interaction is clinically urgent given the prevalence of SSRI use among the target patient population, which creates strong incentives for independent replication. However, 24 months is a short window for five independent published replications — most replication pipelines run 18-36 months from hypothesis to publication. Confidence reduced from 0.78 to 0.58 to reflect this timeline constraint.